CagriSema is a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a glucagon-like peptide-1 receptor agonist.

Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.

Denmark-headquartered Novo Nordisk, a leading global healthcare company founded in 1923 to drive change to defeat serious chronic diseases built upon our heritage in diabetes, announced headline ...

Space Marine 2 launched back in 2023, it felt like everyone and their mum were bisecting Tyranids in the Emperor's name.

Viyaara Realty, a premier Mumbai-based real estate developer, dedicated to creating exceptional living spaces is set to ...

Novo Nordisk stock slumps as the 15.7% weight loss achieved with its next-gen obesity candidate, CagriSema, in the second ...

Amitabh Bachchan’s character to play a more significant role in the sequel. The megastar will return to the sets in May to ...

MFA has the potential to revolutionize cyberdefense in the 21st century. There is value to be gained from delving into its ...

In fintech, where every line of code has the potential to impact the financial ecosystem, one professional stands out for her ...

Neokred, a customer experience platform for business requirements, has partnered with The Akshaya Patra Foundation, the largest NGO led school meal programme, to support the nutrition and education of ...